AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10022422 — intervention group
Group type: COMPARATOR
Intervention: Chronic renal failure (CRF) children
Number of subjects: 0
Study 7502550 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (750 mg per day)
Number of subjects: 18
Study 7502550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg per day) + Simvastatin (20 mg per day)
Number of subjects: 18
Study 7502550 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg per day)
Number of subjects: 18
Study 2079567 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (10 million units subcutaneously, three times a week for 16 weeks) following 6 weeks of prednisone
Number of subjects: 35
Study 2079567 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (10 million units subcutaneously, three times a week for 16 weeks) after 24 weeks of untreated control
Number of subjects: 35
Study 345884 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 30
Study 345884 — intervention group
Group type: COMPARATOR
Intervention: terbutaline
Number of subjects: 30
Study 30352226 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular treatment with the dichoptic binocular Dig Rush iPad game (1 hour per day, 5 days per week) for 8 weeks
Number of subjects: 138
Study 30352226 — intervention group
Group type: COMPARATOR
Intervention: Continued spectacle correction alone
Number of subjects: 138
Study 30352226 — intervention group
Group type: COMPARATOR
Intervention: Comparison of binocular treatment vs. control
Number of subjects: 138
Study 29225440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch use
Number of subjects: 308
Study 29225440 — intervention group
Group type: EXPERIMENTAL
Intervention: Session 8 urges
Number of subjects: 308
Study 29225440 — intervention group
Group type: EXPERIMENTAL
Intervention: Session 1 urges
Number of subjects: 308
Study 29225440 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall decrease in smoking urges
Number of subjects: 308
Study 25886568 — intervention group
Group type: EXPERIMENTAL
Intervention: eCROPS‐CA intervention for 5 years
Number of subjects: 4320
Study 25886568 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 4320
Study 24069481 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily application of the plant-based repellent Zanzarin
Number of subjects: 0
Study 24069481 — intervention group
Group type: COMPARATOR
Intervention: Availability of closed shoes
Number of subjects: 0
Study 24069481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21771745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed oral nutritional supplements containing B‐group vitamins
Number of subjects: 236
Study 21771745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 19448230 — intervention group
Group type: EXPERIMENTAL
Intervention: i.t. morphine (4 microg/kg)
Number of subjects: 50
Study 19448230 — intervention group
Group type: EXPERIMENTAL
Intervention: i.t. morphine and clonidine (1 microg/kg)
Number of subjects: 50
Study 19448230 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 50
Study 16894064 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral intervention (Student Bodies) for 8 weeks
Number of subjects: 480
Study 16894064 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 480
Study 14662111 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids (specific types not mentioned)
Number of subjects: 0
Study 11253275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% sodium fluoride + 2.5% xylitol + 2% sorbitol
Number of subjects: 50
Study 11253275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% sodium fluoride + 12.5% xylitol + 2% sorbitol
Number of subjects: 50
Study 11253275 — intervention group
Group type: COMPARATOR
Intervention: 0.05% sodium fluoride solution
Number of subjects: 50
Study 11253275 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study 9213082 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of sulpiride
Number of subjects: 12
Study 9213082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7960687 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg, once nightly for 4 weeks
Number of subjects: 55
Study 7960687 — intervention group
Group type: COMPARATOR
Intervention: placebo, once nightly for 4 weeks
Number of subjects: 55
Study 7960687 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 55
Study 7960687 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 29083078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort of children born in the early 2010s
Number of subjects: 75
Study 29083078 — intervention group
Group type: COMPARATOR
Intervention: Cohort of children born in the early 2000s
Number of subjects: 75
Study 29083078 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 0-3 years
Number of subjects: 75
Study 29083078 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 4-5 years
Number of subjects: 75
Study 26710892 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 30
Study 26710892 — intervention group
Group type: COMPARATOR
Intervention: SRP + Doxy
Number of subjects: 30
Study 24589566 — intervention group
Group type: EXPERIMENTAL
Intervention: Program and active gaming group
Number of subjects: 75
Study 24589566 — intervention group
Group type: COMPARATOR
Intervention: Program only group
Number of subjects: 75
Study 23208457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanic steroid injection plus conventional steroid treatment (TR group, n=27)
Number of subjects: 53
Study 23208457 — intervention group
Group type: COMPARATOR
Intervention: Conventional steroid treatment (Control group, n=26)
Number of subjects: 53
Study 20650039 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-concurrent amlodipine dosing (simvastatin at 7:00 PM followed by amlodipine at 11:00 PM)
Number of subjects: 17
Study 20650039 — intervention group
Group type: COMPARATOR
Intervention: Concurrent dosing (both drugs at 7:00 PM)
Number of subjects: 17
Study 20650039 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-concurrent amlodipine dosing
Number of subjects: 17
Study 20650039 — intervention group
Group type: COMPARATOR
Intervention: Concurrent dosing
Number of subjects: 17
Study 20650039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (non-concurrent and concurrent)
Number of subjects: 17
Study 17764004 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint therapy
Number of subjects: 59
Study 17764004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-therapy
Number of subjects: 59
Study 17764004 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 16898279 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium tempo music at low and moderate exercise intensities
Number of subjects: 29
Study 16898279 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast tempo music at high exercise intensity
Number of subjects: 29
Study 16898279 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of medium vs slow tempo and fast vs slow tempo music
Number of subjects: 29
Study 16898279 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear relationship between exercise intensity and music tempo preference
Number of subjects: 29
Study 15641498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 208
Study 15641498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus
Number of subjects: 208
Study 10992179 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen
Number of subjects: 10
Study 10992179 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 10
Study 10992179 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel
Number of subjects: 10
Study 10992179 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone
Number of subjects: 10
Study 8806331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolytic therapy (recombinant tissue plasminogen activator)
Number of subjects: 360
Study 8806331 — intervention group
Group type: COMPARATOR
Intervention: Hospital thrombolytic therapy (recombinant tissue plasminogen activator)
Number of subjects: 360
Study 8806331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolytic therapy
Number of subjects: 360
Study 8806331 — intervention group
Group type: COMPARATOR
Intervention: Hospital thrombolytic therapy
Number of subjects: 360
Study 8806331 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy within < 70 minutes from symptom onset
Number of subjects: 360
Study 8806331 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy after 70 minutes from symptom onset
Number of subjects: 360
Study 1293424 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging 2h/week for 4 months
Number of subjects: 33
Study 1293424 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 33
Study 6397969 — intervention group
Group type: EXPERIMENTAL
Intervention: De-Nol liquid (4 X 5 ml)
Number of subjects: 100
Study 6397969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (3 X 50,000 IU)
Number of subjects: 100
Study 6397969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (4 X 1 g)
Number of subjects: 100
Study 6397969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (3 X 50 mg)
Number of subjects: 100
Study 6397969 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 100
Study 30955915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipapkinogen sovacivec (TS) vaccine
Number of subjects: 192
Study 30955915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 29486059 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphoric framing in high-severity condition
Number of subjects: 354
Study 29486059 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphoric framing in low-severity condition
Number of subjects: 354
Study 29486059 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal framing in high-severity condition
Number of subjects: 354
Study 29486059 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal framing in low-severity condition
Number of subjects: 354
Study 29486059 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphoric framing
Number of subjects: 354
Study 29486059 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal framing
Number of subjects: 354
Study 26254687 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SHARE intervention (personalized patient report, educational materials on alcohol and aging, brief provider intervention, telephone health educator intervention)
Number of subjects: 1049
Study 26254687 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SHARE intervention
Number of subjects: 1049
Study 26254687 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1049
Study 25099983 — intervention group
Group type: EXPERIMENTAL
Intervention: Live saxophone music therapy for 30 minutes
Number of subjects: 52
Study 25099983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 21924651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulathromycin intramuscularly
Number of subjects: 128
Study 21924651 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin monotherapy orally
Number of subjects: 128
Study 21924651 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin in combination with rifampin orally
Number of subjects: 128
Study 21924651 — intervention group
Group type: COMPARATOR
Intervention: Glucose orally as a placebo
Number of subjects: 128
Study 20433566 — intervention group
Group type: EXPERIMENTAL
Intervention: New daytime at-home bleaching system (28% carbamide peroxide gel) with a non-custom-fit tray for 20 minutes
Number of subjects: 20
Study 20433566 — intervention group
Group type: COMPARATOR
Intervention: Conventional overnight at-home bleaching system (10% carbamide peroxide gel) with a custom-fit tray for 6 to 8 hours
Number of subjects: 20
Study 18536860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg once daily
Number of subjects: 224
Study 18536860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 16189335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg x kg(‐1) ketamine (Group K)
Number of subjects: 60
Study 16189335 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 60
Study 16189335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg x kg(‐1) ketamine and 0.25% bupivacaine (Group BK)
Number of subjects: 60
Study 16189335 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study 12378045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg oral ascorbic acid (AA) preoperatively
Number of subjects: 54
Study 12378045 — intervention group
Group type: COMPARATOR
Intervention: No ascorbic acid (AA) preoperatively
Number of subjects: 54
Study 10434238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg twice daily for 10 days)
Number of subjects: 12
Study 10434238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 10 days)
Number of subjects: 12
Study 7810935 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aspiration of subglottic secretions
Number of subjects: 190
Study 7810935 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study 1971741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 15
Study 1971741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 15
Study 1971741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 15
Study 1971741 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg (positive control)
Number of subjects: 15
Study 1971741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 15
Study 423667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (diaminodiphenylsulfone)
Number of subjects: 64
Study 423667 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 64
Study 31269044 — intervention group
Group type: EXPERIMENTAL
Intervention: Main perpetrator programme
Number of subjects: 228
Study 29412076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR; ∼800 mg/d)
Number of subjects: 52
Study 29412076 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA; ∼0.5 mg/d)
Number of subjects: 52
Study 27009147 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved stem THA (Collum Femoris Preserving stem)
Number of subjects: 150
Study 27009147 — intervention group
Group type: COMPARATOR
Intervention: Straight stem THA (conventional uncemented straight stem)
Number of subjects: 150
Study 24905687 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-care management under continuous regional anaesthesia (popliteal sciatic nerve block)
Number of subjects: 120
Study 24905687 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management under continuous regional anaesthesia (popliteal sciatic nerve block)
Number of subjects: 120
Study 22918596 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine + Selenomethionine
Number of subjects: 155
Study 22918596 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 155
Study 22918596 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 155
Study 22918596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 22918596 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 155
Study 20113411 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 640 microg/cm(2), 8%)
Number of subjects: 0
Study 20113411 — intervention group
Group type: COMPARATOR
Intervention: Control patch
Number of subjects: 0
Study 18030234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) monotherapy
Number of subjects: 31
Study 18030234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus lamivudine combination therapy
Number of subjects: 31
Study 12043854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg twice daily
Number of subjects: 0
Study 12043854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.5 mg twice daily
Number of subjects: 0
Study 12043854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12798837 — intervention group
Group type: EXPERIMENTAL
Intervention: Management group (heart failure diary, education sessions)
Number of subjects: 197
Study 12798837 — intervention group
Group type: EXPERIMENTAL
Intervention: Management group (self-weighing)
Number of subjects: 197
Study 12798837 — intervention group
Group type: EXPERIMENTAL
Intervention: Management group (knowledge of self-management)
Number of subjects: 197
Study 12798837 — intervention group
Group type: EXPERIMENTAL
Intervention: Management group (daily weight monitoring)
Number of subjects: 197
Study 12798837 — intervention group
Group type: EXPERIMENTAL
Intervention: Management group (attendance at education sessions)
Number of subjects: 197
Study 12798837 — intervention group
Group type: EXPERIMENTAL
Intervention: Management group (provision of scales)
Number of subjects: 197
Study 12798837 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 197
Study 10344223 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening protocol including PSA, DRE, and TRUS
Number of subjects: 1000
Study 10344223 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening protocol
Number of subjects: 1000
Study 10344223 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive index model
Number of subjects: 1000
Study 7560229 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 10
Study 7560229 — intervention group
Group type: COMPARATOR
Intervention: Saline and alcohol solutions
Number of subjects: 10
Study 2020505 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based, lactose-free formula alternating with oral rehydration solution (early feeding)
Number of subjects: 56
Study 2020505 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution alone (control group)
Number of subjects: 56
Study 6760074 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 antagonist (diphenhydramine 50 mg iv)
Number of subjects: 10
Study 6760074 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 antagonist (cimetidine 300 mg iv)
Number of subjects: 10
Study 6760074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31888726 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher Anxiety Program for Elementary Students (TAPES)
Number of subjects: 0
Study 31888726 — intervention group
Group type: COMPARATOR
Intervention: Standard professional development seminar
Number of subjects: 0
Study 28334365 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib for 3 years
Number of subjects: 341
Study 28334365 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant imatinib for 1 year
Number of subjects: 341
Study 26363442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptic II
Number of subjects: 30
Study 26363442 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Posterior (CP)
Number of subjects: 30
Study 26363442 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusin (O)
Number of subjects: 30
Study 26363442 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 30
Study 26363442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23471307 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis
Number of subjects: 897
Study 23471307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic G-CSF
Number of subjects: 897
Study 23471307 — intervention group
Group type: COMPARATOR
Intervention: Mandatory hospitalization
Number of subjects: 897
Study 21360596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg, single oral dose)
Number of subjects: 6
Study 19532050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0
Study 19532050 — intervention group
Group type: EXPERIMENTAL
Intervention: New ART agents and fixed-dose combinations
Number of subjects: 0
Study 19532050 — intervention group
Group type: EXPERIMENTAL
Intervention: ART adherence
Number of subjects: 0
Study 19532050 — intervention group
Group type: EXPERIMENTAL
Intervention: cART initiation
Number of subjects: 0
Study 17601463 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings in the neutral position
Number of subjects: 29
Study 17601463 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings in the provocative position
Number of subjects: 29
Study 17601463 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional change values in MRI
Number of subjects: 29
Study 17601463 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum costoclavicular distance
Number of subjects: 29
Study 15122774 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (n = 20)
Number of subjects: 55
Study 15122774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermentable fiber alone (n = 20)
Number of subjects: 55
Study 15122774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 55
Study 10791112 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with Chlamydia pneumoniae
Number of subjects: 0
Study 10791112 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with Mycoplasma pneumoniae
Number of subjects: 0
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy (n = 61)
Number of subjects: 152
Study 9116392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 152
Study 9116392 — intervention group
Group type: COMPARATOR
Intervention: PA spine BMD
Number of subjects: 152